UBS has raised its price target for Sartorius from 264 euros to 278 euros after the company's third-quarter results were released. The Swiss bank has kept its "Neutral" rating on the laboratory services provider's shares.
Analyst Matthew Weston stated that the revised target is due to higher valuations in the industry. The updated price target reflects a positive outlook for Sartorius in a favorable market environment.
The analysis was published on October 21, 2024, and highlights ongoing trends in the laboratory services sector that could impact investor sentiment.